CSPC Pharma of Shijiazhuang announced two out-licensings from its generic drug portfolio that will bring in up to $201 million in milestones plus royalties. Through its subsidiary, CSPC Zhongqi Pharma, CSPC out-licensed US and EU rights for a development-stage complex injectible generic antibiotic to Teva Pharma for $100 million, and it licensed US rights for a complex generic oncology to Citron Pharma of New Jersey for $101 million in milestones. CSPC already sells the oncology product in China.
